Finally, in the independent validation cohort, we found that EPCR and CETP were better than CPB2 for predicting MACEs in patients with CCS by ELISA and, when combined with the Framingham coronary heart disease (CHD) risk model, they improved the risk prediction beyond the Framingham CHD risk model alone. This evidence concerns the gene PROCR and coronary artery disorder.